Elzonris, also known as tagraxofusp, is a medication that has been approved by the FDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive form of blood cancer. This drug works by targeting and binding to CD123, a protein that is overexpressed on the surface of BPDCN cells, leading to their destruction.

Elzonris is typically administered intravenously over a period of several days, followed by a rest period before the next cycle of treatment. The dosage and frequency of administration will be determined by your healthcare provider based on your individual condition and response to the medication.

As with any medication, Elzonris may cause side effects. Common side effects may include nausea, fatigue, fever, and swelling at the injection site. More serious side effects, such as liver toxicity and capillary leak syndrome, may also occur and should be reported to your healthcare provider immediately.

It is important to follow your healthcare provider’s instructions carefully while taking Elzonris. This may include regular blood tests to monitor your response to the medication and any potential side effects. It is also important to communicate openly with your healthcare team about any concerns or changes in your condition while taking this medication.

Overall, Elzonris represents a promising treatment option for individuals with BPDCN, offering hope for improved outcomes and quality of life. If you have been diagnosed with BPDCN, talk to your healthcare provider about whether Elzonris may be a suitable treatment option for you.